Loading
Latest filing published 03 Apr 2026 for 셀트리온제약, €48.
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
최덕규, listed as chief executive, appears in our data through filings on 셀트리온제약 shares, published by DART (FSS). In total, 4 filings cover trades dated from 26 March 2024 to 24 March 2026.
Purchases make up the whole of the open-market record (4 purchases, €104). The totals exclude 2 filings filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2026, the count stands at 1 purchase and no sales.
The record was last updated on 3 April 2026 with an open-market purchase (€48) in 셀트리온제약. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations